Fig. 4From: Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysisForest plots for predictive analyses of PIK3CA mutations in trials comparing experimental arm with control arm—a, b progression-free survival and c, d overall survival. PFS, progression-free survival; OS overall survivalBack to article page